Author(s):
Ajmer Singh Grewal, Komal Thapa, Anil Bansal, Deepshikha, Neelam Sharma, Sukhbir Singh
Email(s):
sukhbir.singh@chitkara.edu.in
DOI:
10.5958/0974-360X.2020.00699.X 
Address:
Ajmer Singh Grewal1, Komal Thapa1, Anil Bansal2, Deepshikha2, Neelam Sharma2, Sukhbir Singh2
1Chitkara University School of Basic Sciences, Chitkara University, Himachal Pradesh, India.
2Chitkara College of Pharmacy, Chitkara University, Punjab, India.
*Corresponding Author
Published In:
Volume - 13,
Issue - 8,
Year - 2020
ABSTRACT:
The progression of liver disease involves the most crucial pathogenic events; oxidative stress and inflammation. Nuclear erythroid 2-related factor 2 (Nrf2) has been regarded as the master regulator of gene expression that are involved in cellular protection via exerting antioxidant, cytoprotective and anti-inflammatory effects. Numerous compounds have been tested as Nrf2 activators including natural (resveratrol, epigallocatechin-3 and curcumin) as well as synthetic compounds (bardoxolone methyl, oltipraz and anethole dithiol ethione) that prevent interaction of Nrf2 with Kelch-like ECH-associated protein 1 (Keap1) due to modification in cysteine sulfhydryl groups of Keap1. The current review demonstrates the function of Nrf2 in various liver diseases; acute liver failure, alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD) and also holds recent studies for the identification of novel drug upregulating Nrf2. There is no approved treatment for liver diseases. Currently oltipraz which is an activator of Nrf2 is in Phase III clinical evaluation for NAFLD; more preclinical and clinical evaluation of drugs as Nrf2 activators is still needed to develop a new treatment strategy for liver disorders.
Cite this article:
Ajmer Singh Grewal, Komal Thapa, Anil Bansal, Deepshikha, Neelam Sharma, Sukhbir Singh. Therapeutic role of nuclear factor erythroid-2 related factor 2 (Nrf2) in liver disorders. Research J. Pharm. and Tech. 2020; 13(8):3952-3956. doi: 10.5958/0974-360X.2020.00699.X
Cite(Electronic):
Ajmer Singh Grewal, Komal Thapa, Anil Bansal, Deepshikha, Neelam Sharma, Sukhbir Singh. Therapeutic role of nuclear factor erythroid-2 related factor 2 (Nrf2) in liver disorders. Research J. Pharm. and Tech. 2020; 13(8):3952-3956. doi: 10.5958/0974-360X.2020.00699.X Available on: https://rjptonline.org/AbstractView.aspx?PID=2020-13-8-72
REFERENCES:
1. Muriel P. Role of free radicals in liver diseases. Hepatology International. 2009; 3(4): 526-536.
2. Fauzi NQBA, Vishnupriya V and Gayathri R Fatty liver disease - a review. Research Journal of Pharmacy and Technology. 2016; 9(8): 1263-1267.
3. Vomund S, et al. NRF2, the master regulator of anti-oxidative responses. International Journal of Molecular Sciences. 2017; 18(12): E2772.
4. Chowdhry S, et al. Loss of NRF2 markedly exacerbates nonalcoholic steatohepatitis. Free Radical Biology and Medicine. 2010; 48(2): 357-371.
5. Boutten A, et al. NRF2 targeting: a promising therapeutic strategy in chronic obstructive pulmonary disease. Trends in Molecular Medicine. 2011; 17(7): 363-371.
6. Sandberg M, et al. NRF2-regulation in brain health and disease: implication of cerebral inflammation. Neuropharmacology. 2014; 79: 298-306
7. Bellezza I. Oxidative stress in age-related macular degeneration: Nrf2 as therapeutic target. Frontiers in Pharmacology. 2018; 9: 1280.
8. Thimmulappa RK, et al. Preclinical evaluation of targeting the NRF2 pathway by triterpenoids (CDDO-Im and CDDO-Me) for protection from LPS-induced inflammatory response and reactive oxygen species in human peripheral blood mononuclear cells and neutrophils. Antioxidants and Redox Signaling. 2007; 9(11): 1963-1970.
9. Sussan TE, et al. Targeting NRF2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106(1): 250-255.
10. Xu D, et al. The role of NRF2 in liver disease: novel molecular mechanisms and therapeutic approaches. Frontiers in Pharmacology. 2018; 9: 1428.
11. Bataille AM and Manautou JE. NRF2: a potential target for new therapeutics in liver disease. Clinical Pharmacology and Therapeutics. 2012; 92(3): 340-348.
12. Karin M and Dhar D. Liver carcinogenesis: from naughty chemicals to soothing fat and the surprising role of NRF2. Carcinogenesis. 2016; 37(6): 541-546.
13. de la Vega MR, Chapman E and Zhang DD. NRF2 and the hallmarks of cancer. Cancer Cell. 2018; 34(1): 21-43.
14. Kensler TW, Wakabayashi N and Biswal S. Cell survival responses to environmental stresses via the Keap1-NRF2-ARE pathway. Annual Review of Pharmacology and Toxicology. 2007; 47, 89-116.
15. Paupe V, et al. Impaired nuclear NRF2 translocation undermines the oxidative stress response in Friedreich ataxia. PloS One. 2009; 4(1): E4253.
16. Ke B, et al. KEAP1-NRF2 complex in ischemia-induced hepatocellular damage of mouse liver transplants. Journal of Hepatology. 2013; 59(6): 1200-1207.
17. Fan X, et al. Dynamic and coordinated regulation of KEAP1-NRF2-ARE and p53/p21 signaling pathways is associated with acetaminophen injury responsive liver regeneration. Drug Metabolism and Disposition. 2014; 42(9): 1532-1539.
18. Lu MC, et al. The Keap1–NRF2–ARE pathway as a potential preventive and therapeutic target: an update. Medicinal Research Reviews. 2016; 36(5): 924-963.
19. Chi X, et al. Sulforaphane reduces apoptosis and oncosis along with protecting liver injury-induced ischemic reperfusion by activating the NRF2/ARE pathway. Hepatology International. 2015; 9(2): 321-329.
20. Liu X, et al. Biochanin A protects lipopolysaccharide/D-galactosamine-induced acute liver injury in mice by activating the NRF2 pathway and inhibiting NLRP3 inflammasome activation. International Immunopharmacology. 2016; 38: 324-331.
21. Pan CW, et al. Andrographolide ameliorates d-galactosamine/lipopolysaccharide induced acute liver injury by activating NRF2 signaling pathway. Oncotarget. 2017; 8: 41202-41210.
22. Xie YL, et al. Curcumin attenuates lipopolysaccharide/d-galactosamine-induced acute liver injury by activating NRF2 nuclear translocation and inhibiting NF-kB activation. Biomedicine and Pharmacotherapy. 2017; 91: 70-77.
23. Tian Y, et al. Protective effects of morin on lipopolysaccharide/d-galactosamine-induced acute liver injury by inhibiting TLR4/NF-kappaB and activating NRF2/HO-1 signaling pathways. International Immunopharmacology. 2017; 45: 148-155.
24. Wang W, et al. Madecassoside prevents acute liver failure in LPS/D-GalN-induced mice by inhibiting p38/NFkappaB and activating NRF2/HO-1 signaling. Biomedicine and Pharmacotherapy. 2018; 103: 1137-1145.
25. Huang YJ, et al. Protection against acetaminophen-induced acute liver failure by omentumadipose tissue derived stem cells through the mediation of NRF2 and cytochrome P450 expression. Journal of Biomedical Science. 2016; 23: 5.
26. Cao M, et al. Dibenzoylmethane protects against CCl4-induced acute liver injury by activating NRF2 via JNK, AMPK, and calcium signaling. AAPS Journal. 2017; 19: 1703-1714.
27. Peng X, et al. Curcumin attenuates on carbon tetrachloride-induced acute liver injury in mice via modulation of the NRF2/HO-1 and TGF-beta1/Smad3 pathway. Molecules. 2018; 23: E215.
28. Shen F, et al. Ethyl pyruvate can alleviate alcoholic liver disease through inhibiting NRF2 signaling pathway. Experimental and Therapeutic Medicine. 2018; 15: 4223-4228.
29. Kudoh K, et al. NRF2 activation protects the liver from ischemia/reperfusion injury in mice. Annals of Surgery. 2014; 260: 118-127.
30. Rao J, et al. ATF3-mediated NRF2/HO-1 signaling regulates TLR4 innate immune responsesin mouse liver ischemia/reperfusion injury. Am. J. Transplant 2015; 15: 76-87.
31. Xu D, et al. (2017). The triterpenoid CDDO-imidazolide ameliorates mouse liver ischemia-reperfusion injury through activating the NRF2/HO-1 pathway enhanced autophagy. Cell Death and Disease. 2017; 8: E2983.
32. Shepard BD, Tuma DJ and Tuma PL. Chronic ethanol consumption induces global hepatic protein hyperacetylation. Alcoholism: Clinical and Experimental Research. 2010; 34: 280-291.
33. Dey A and Cederbaum AI. Alcohol and oxidative liver injury. Hepatology. 2006; 43: S63-S74.
34. Harvey CJ, et al. NRF2-regulated glutathione Free Radical Biology and Medicine. 2009; 46, 443-453.
35. Lu SC. Glutathione synthesis. Biochimica et Biophysica Acta. 2013; 2013: 3143-3153.
36. Rejitha S, Prathibha P and Indira M. NRF2-mediated antioxidant response by ethanolic extract of Sidacordifolia provides protection against alcohol-induced oxidative stress in liver by upregulation of glutathione metabolism. Redox Report. 2015; 20: 75-80.
37. Dong J, Sulik KK and Chen SY. NRF2-mediated transcriptional induction of antioxidant response in mouse embryos exposed to ethanol in vivo: implications for the prevention of fetal alcohol spectrum disorders. Antioxidants and Redox Signaling. 2008; 10: 2023-2033.
38. Song X, et al. Glycycoumarin ameliorates alcohol-induced hepatotoxicity via activation of NRF2 and autophagy. Free Radical Biology and Medicine. 2015; 89: 135-146.
39. Lu C, et al. NRF2 knockdown disrupts the protective effect of curcumin on alcohol-induced hepatocyte necroptosis. Molecular Pharmaceutics. 2016; 13: 4043-4053.
40. Ni YH, Huo LJ and Li TT. Antioxidant axis NRF2-Keap1-ARE in inhibition of alcoholic liver fibrosis by IL-22. World J. Gastroenterology. 2017; 23: 2002-2011.
41. Fawcett TW, et al. Complexes containing activating transcription factor (ATF)/cAMP-responsive element- binding protein (CREB) interact with the CCAAT/enhancer-binding protein (C/EBP)-ATF composite site to regulate Gadd153 expression during the stress response. Biochemical Journal. 1999; 339(Pt 1): 135-141.
42. Harding HP, et al. Perk is essential for translational regulation and cell survival during the unfolded protein response. Molecular Cell 2000; 5: 897-904.
43. Satapathy SK and Sanyal AJ. Epidemiology and natural history of nonalcoholic fatty liver disease. Semin. Liver Disease. 2015; 35: 221-235.
44. Choudhari S and Jothipriya A. Non-Alcoholic Fatty Liver Disease. Research Journal of Pharmacy and Technology. 2016; 9(10): 1782-1785.
45. Tarantino G and Finelli C. Pathogenesis of hepatic steatosis: the link between hypercortisolism and non-alcoholic fatty liver disease. World Journal of Gastroenterology. 2013; 19: 6735-6743.
46. Dietrich P, and Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Practice and Research Clinical Gastroenterology. 2014; 28: 637-653.
47. Chambel SS, Goncalves AS and Duarte TL. The dual role of NRF2 in nonalcoholic fatty liver disease: regulation of antioxidant defenses and hepatic lipid metabolism. Biomedical Research International. 2015; 2015: 597134.
48. Du J, et al. Osteocalcin improves nonalcoholic fatty liver disease in mice through activation of NRF2and inhibition of JNK. Endocrine. 2016; 53: 701-709.
49. Zhang X., et al. Scutellarin ameliorates nonalcoholic fatty liver disease through the PPARgamma/PGC-1alpha-NRF2 pathway. Free Radical Research. 2018; 52: 198-211.
50. Feng X, et al. Apigenin, a modulator of PPARgamma, attenuates HFD-induced NAFLD by regulating hepatocyte lipid metabolism and oxidative stress via NRF2 activation. Biochemical Pharmacology. 2017; 136: 136-149.
51. Gupte AA, Lyon CJ and Hsueh WA. Nuclear factor (erythroid derived 2)-like-2 factor (NRF2), a key regulator of the antioxidant response to protect against atherosclerosis and nonalcoholic steatohepatitis. Current Diabetes Reports. 2013; 13: 362-371.
52. Chowdhry S, et al. Loss of NRF2 markedly exacerbates nonalcoholic steatohepatitis. Free Radic. Biology and Medicine. 2010; 48: 357-371.
53. Wang C, et al. NRF2 deletion causes “benign” simple steatosis to develop into nonalcoholic steatohepatitis in mice fed a high-fat diet. Lipids in Health and Disease. 2013; 12: 165.
54. Ramadori P, et al. Genetic NRF2 overactivation inhibits the deleterious effects induced by hepatocyte-specific c-met deletion during the progression of NASH. Oxidative Medicine and Cellular Longevity. 2017; 2017: 3420286.
55. Lee DH, et al. Ezetimibe, an NPC1L1 inhibitor, is a potent NRF2 activator that protects mice from diet-induced nonalcoholic steatohepatitis. Free Radical Biology and Medicine. 2016; 99: 520-532.
56. Li J, et al. Green tea extract provides extensive NRF2-independent protection against lipid accumulation and NFkappaB pro- inflammatory responses during nonalcoholic steatohepatitis in mice fed a high-fat diet. Molecular Nutrition and Food Research. 2016; 60: 858-870.
57. Chen X, et al. Adropin protects against liver injury in nonalcoholic steatohepatitis via the NRF2 mediated antioxidant capacity. Redox Biology. 2019; 21: 101068.
58. Kwak MK, et al. Role of transcription factor NRF2 in the induction of hepatic phase 2 and antioxidative enzymes in vivo by the cancer chemoprotective agent, 3 H-1, 2-dithiole-3-thione. Molecular Medicine. 2001; 7(2): 135.
59. Mohamed MZ, et al. PI3K/Akt and NRF2/HO-1 pathways involved in the hepatoprotective effect of verapamil against thioacetamide toxicity in rats. Human and Experimental Toxicology. 2019; 38(4): 381-388.
60. Xu YY, Shen FJ and Wu LL. Effect of benazepril on nuclear factor E2 related factor 2, nicotinamide adenine dinucleotide phosphate oxidase and reactive oxygen species in rats with hepatic fibrosis. Chinese Journal of Hepatology. 2019; 27(9): 677-680.
61. Ji Y, et al. Sitagliptin protects liver against aflatoxin B1‐induced hepatotoxicity through upregulating NRF2/ARE/HO‐1 pathway. BioFactors. 2019; [Epub ahead of print].
62. Yu Y, et al. Babao Dan attenuates acute ethanol-induced liver injury via NRF2 activation and autophagy. Cell and Bioscience. 2019; 9(1): 1-12.
63. Sun B, et al. Sodium butyrate protects against high-fat diet-induced oxidative stress in rat liver by promoting expression of nuclear factor E2-related factor 2. British Journal of Nutrition. 2019; 122(4): 400-410.
64. Wang J and Guo H. Astragaloside IV ameliorates high glucose induced HK 2 cell apoptosis and oxidative stress by regulating the NRF2/ARE signaling pathway. Experimental and Therapeutic Medicine. 2019; 17(6): 4409-4416.
65. Fang S, et al. Exendin-4 alleviates oxidative stress and liver fibrosis by activating NRF2/HO-1 in streptozotocin-induced diabetic mice. Journal of Southern Medical University. 2019; 39(4): 464-470
66. Thangapandiyan S, et al. Sulforaphane potentially ameliorates arsenic induced hepatotoxicity in albino Wistar rats: implication of PI3K/Akt/NRF2 signaling pathway. Cellular Physiology and Biochemistry. 2019; 52(5): 1203-1222.
67. Tian Y, et al. Protective effects of Coreopsis tinctoria flowers phenolic extract against D-galactosamine/lipopolysaccharide-induced acute liver injury by up-regulation of NRF2, PPARα, and PPARγ. Food and Chemical Toxicology. 2018; 121: 404-412.
68. Ning C, et al. Ginsenoside Rg1 protects against acetaminophen-induced liver injury via activating NRF2 signaling pathway in vivo and in vitro. Regulatory Toxicology and Pharmacology. 2018; 98: 58-68.
69. Shu G, et al. Nuciferine alleviates acute alcohol-induced liver injury in mice: Roles of suppressing hepatic oxidative stress and inflammation via modulating miR-144/NRF2/HO-1 cascade. Journal of Functional Foods. 2019; 58: 105-113.
70. Dkhil MA, et al. Myristica fragrans kernels prevent paracetamol-induced hepatotoxicity by inducing anti-apoptotic genes and NRF2/HO-1 pathway. International Journal of Molecular Sciences. 2019; 20(4): E993.
71. Zhou Y, et al. Gallic acid protects against ethanol-induced hepatocyte necroptosis via an NRF2-dependent mechanism. Toxicology in Vitro. 2019; 57: 226-232.
72. Yang JH, et al. Bamboo stems (Phyllostachys nigra variety henosis) containing polyphenol mixtures activate NRF2 and attenuate phenylhydrazine-induced oxidative stress and liver injury. Nutrients. 2019; 11(1): 114
73. Li Z, et al. Rosmarinic acid protects mice from lipopolysaccharide/d-galactosamine-induced acute liver injury by inhibiting MAPKs/NF-κB and activating NRF2/HO-1 signaling pathways. International Immunopharmacology. 2019; 67: 465-472.
74. Affrin JH and Savitha G. Serum gamma glutamyl transferase activity in liver diseases. Research Journal of Pharmacy and Technology. 2018; 11(1): 387-389.
75. Maity T, et al. A review on hepatoprotective herbs for treatment of various liver disorders. Research Journal of Pharmacy and Technology. 2012; 5(5): 602-607.
76. Liu C, et al. Torularhodin Ameliorates Oxidative Activity in Vitro and d-Galactose-Induced Liver Injury via the Nrf2/HO-1 Signaling Pathway in Vivo. Journal of Agricultural and Food Chemistry. 2019; 67(36): 10059-10068.